2024

On June 20, as reported by the Journal Citation Reports (JCR) by Clarivate Analytics, Cancer Drug Resistance (CDR) achieved a new 2023 Impact Factor of 4.6, earning a Q1 ranking in Oncology.

In June, the 2023 CiteScore of Cancer Drug Resistance (CDR) was released by Scopus, showing an impressive rise from 5.5 to 6.6 and placing the journal in Q1 in the field of Pharmacology (medical).

In January, CDR has shifted from quarterly to continuous publication. This change also signifies that each article will be promptly indexed in PubMed Central® (PMC) upon publication.

2023

In July, the new column of Cancer Drug Resistance (CDR) - "Special Collection" was officially launched.

On June 28, as announced by Clarivate Analytics in the Journal Citation Reports (JCR), Journal of the Cancer Drug Resistance (CDR) has achieved its first Impact Factor of 3.7.

In June, the 2022 CiteScore of Cancer Drug Resistance (CDR) reached 5.5, placing the journal in the top 30% of journals in Pharmacology (medical) and in the top 50% in Cancer Research.

2022

In August, CDR is accepted for inclusion in Emerging Sources Citation Index (ESCI).

In May, CDR is officially indexed in PubMed Central® (PMC).

2021

In March, CDR was indexed in Scopus.

2019

In March, CDR became a member of the Committee on Publication Ethics (COPE).

2018

In March, CDR was founded with Professor Godefridus J. Peters as the Editor-in-Chief. The inaugural issue was officially released online on March 19, 2018.